Canaccord Genuity Thinks Orasure Technologies’ Stock is Going to Recover


In a report issued on January 4, Mark Massaro from Canaccord Genuity reiterated a Buy rating on Orasure Technologies (OSUR), with a price target of $18. The company’s shares closed on Friday at $11.85, close to its 52-week low of $10.27.

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 12.0% and a 53.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.

Currently, the analyst consensus on Orasure Technologies is a Moderate Buy with an average price target of $16.33.

See today’s analyst top recommended stocks >>

Based on Orasure Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $8.1 million. In comparison, last year the company had a net profit of $7.32 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts